Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3099% above fair value
$144.67−3.69 (-2.49%)
Close on Nov 3, 2026Market cap $356.93BP/E 149.1Yield 2.27%
Merck Bravecto — Worldwide reported growth YoY by Quarter
Bravecto — Worldwide reported growth YoY (%) (%)
Merck Bravecto — Worldwide reported growth YoY: 7.0% in Q2 2026, up 6.0 pts from a year earlier.
Latest, Q2 2026
7.0%
Period ended Jun 30, 2026
Change on a year earlier
+6.0 pts
1.0% in Q2 2025
History
5 quarters
Since Q3 2023
Sources
5
Documents cited below
Where the Q2 2026 figure comes from
“Sales of the Bravecto (fluralaner) line of products were $359 million in the second quarter of 2026, representing growth of 7%, or 4% excluding the effect of foreign exchange, compared with the second quarter of 2025.”
Source: Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Animal Health MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bravecto — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 7.0% | +6.0 pts | Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 16.0% | – | Form 10-Q (mrk-20260331.htm, filed 2026-05-04) ↗ |
| Q3 2025 | Sep 30, 2025 | -1.0% | – | Form 10-Q (mrk-20250930.htm, filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1.0% | – | Form 10-Q (mrk-20250630.htm, filed 2025-08-05) ↗ |
| Q3 2023 | Sep 30, 2023 | -3.0% | – | Form 10-Q (mrk-20230930.htm, filed 2023-11-03) ↗ |
Cite this data
StockData. (2026). Merck Bravecto — Worldwide reported growth YoY (%), quarterly Q3 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-bravecto-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?